menopausal women exhibit endogenous cardioprotective signaling mechanisms that are thought to result from the beneficial effects of estrogen, which we have shown to increase protein S-nitrosylation in the heart. S-nitrosylation is a labile protein modification that increases with a number of different forms of cardioprotection, including ischemic preconditioning. Herein, we sought to identify a potential role for protein S-nitrosylation in sex-dependent cardioprotection. We utilized a Langendorff-perfused mouse heart model of ischemia-reperfusion injury with male and female hearts, and S-nitrosylation-resin-assisted capture with liquid chromatography tandem mass spectrometry to identify S-nitrosylated proteins and modification sites. Consistent with previous studies, female hearts exhibited resilience to injury with a significant increase in functional recovery compared with male hearts. In a separate set of hearts, we identified a total of 177 S-nitrosylated proteins in female hearts at baseline compared with 109 S-nitrosylated proteins in male hearts. Unique S-nitrosylated proteins in the female group included the F 1FO-ATPase and cyclophilin D. We also utilized label-free peptide analysis to quantify levels of common S-nitrosylated identifications and noted that the S-nitrosylation of sarcoplasmic/endoplasmic reticulum Ca 2ϩ -ATPase 2a was nearly 70% lower in male hearts compared with female, with no difference in expression. Furthermore, we found a significant increase in endothelial nitric oxide synthase expression, phosphorylation, and total nitric oxide production in female hearts compared with males, likely accounting for the enhanced S-nitrosylation protein levels in female hearts. In conclusion, we identified a number of novel S-nitrosylated proteins in female hearts that are likely to contribute to sex-dependent cardioprotection. sex differences; ischemia-reperfusion injury; cardioprotection; S-nitrosylation; endothelial nitric oxide synthase; S-nitrosoglutathione reductase
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NEW & NOTEWORTHY

This is the first study to use a high-throughput proteomics approach to identify S-nitrosylated proteins and modification sites in male and female hearts. Female hearts exhibited nearly 65% more S-nitrosylated proteins compared with male, the majority of which are novel and likely to play a role in sex-dependent cardioprotection.
ISCHEMIC HEART DISEASE IS a major cause of mortality among men and women in the United States (35) . Interestingly, premenopausal women have a reduced risk for the development of cardiovascular disease, and, compared with agematched men, premenopausal women have a lower incidence of coronary artery disease, left ventricular hypertrophy, and cardiac remodeling after myocardial infarction (4, 9, 19) . Preclinical studies provide further support for sex-dependent cardioprotection (36) , as animal studies have demonstrated improved postischemic functional recovery and smaller infarct sizes in female hearts following ischemia-reperfusion (I/R) injury compared with males (3, 20, 44, 51) , although this male-female difference has not been observed in all reports (29, 42) . Our group has also demonstrated a consistent protective effect in female hearts subjected to I/R injury in the setting of enhanced contractility and/or cellular Ca 2ϩ -handling (i.e., ␤-adrenergic stimulation) (10, 48) . However, the mechanism underlying this protection in premenopausal female hearts remains to be fully elucidated.
Nitric oxide (NO) is emerging as a key signaling molecule in the heart, with the constitutive isoforms of NO synthase (NOS), endothelial (eNOS) and neuronal (nNOS), serving as the primary source of NO in cardiomyocytes (15) . In the female heart, NOS expression is increased compared with male hearts (10, 45, 48) , and inhibition or genetic deletion of eNOS or nNOS abrogates protection in female hearts, pointing to a role for NO in this pathway (48) . During acute I/R injury, NO signals primarily through protein S-nitrosothiol (SNO) formation, a specific and reversible cysteine modification resulting from the covalent attachment of NO. The actions of SNO are diverse with potential effects on protein function and stability (15) ; our laboratory and others have also demonstrated that SNO can protect against irreversible cysteine oxidation (8, 23, 24) . In previous studies, our laboratory noted increased protein SNO with many different forms of cardioprotection (24, 47, 49) , including sex-dependent protection (31, 48) . For example, Sun et al. (48) showed enhanced SNO of the L-type Ca 2ϩ channel in the female mouse heart, and this correlated with reduced channel activity and decreased Ca 2ϩ overload following I/R injury. Our laboratory has also shown that estrogen treatment increases protein SNO in the myocardium (31) . However, the specific SNO modification sites and the relative importance of enhanced SNO have not been characterized in the female heart.
In the present study, we utilized SNO-resin-assisted capture (SNO-RAC) in tandem with mass spectrometry as a highthroughput approach to map specific SNO modification sites for the first time in male and female mouse hearts. We identified nearly 200 unique SNO proteins in female hearts, and, consistent with previous reports, female hearts exhibited nearly 65% more SNO protein identifications compared with male hearts. In addition, we show evidence of enhanced eNOS expression and phosphorylation in female hearts, as well as increased eNOS-dependent total NO (NO x ) production, suggesting a potential role for eNOS in the enhancement of SNO protein levels in female hearts.
MATERIALS AND METHODS
Animals.
Male and female C57BL/6J mice were obtained from the Jackson Laboratory (Bar Harbor, ME). All animals utilized in this study were between the ages of 12-18 wk. For all procedures, mice were anesthetized with a mixture of ketamine (Hofspira, Lake Forest, IL; 90 mg/kg) and xylazine (Sigma, St. Louis, MO; 10 mg/kg) via intraperitoneal injection and anticoagulated with heparin (Fresenvis Kabi, Lake Zurich, IL 
Cayman Chemical) were used as selective and nonselective inhibitors of NOS activity, respectively. Nitrosoglutathione (GSNO; Sigma) was used as a substrate for S-nitrosoglutathione reductase (GSNO-R). All solutions were made fresh on the day of experimentation.
I/R treatment protocol. Hearts were excised from male and female mice and placed in ice-cold KHB. The aorta was cannulated, and the heart was perfused in a retrograde fashion on a Langendorff apparatus with KHB at a constant pressure of 100 cmH 2O at 37°C in the dark, to prevent light-induced cleavage of SNO. Male and female hearts were then subjected to an I/R protocol ( Fig. 1A ; 20-min equilibration period, 20-min ischemic period, 30-min reperfusion period). A latex balloon connected to a pressure transducer was inserted into the left ventricle to measure left ventricular developed pressure (LVDP); LVDP and heart rate were recorded and digitized through a PowerLab system (AD Instruments, Dunedin, New Zealand). The rate pressure product was calculated and used as a measure of cardiac contractile function. Postischemic functional recovery was expressed as a percentage of the preischemic rate pressure product.
Whole heart homogenate preparation. Whole heart homogenates were prepared as described previously (22, 24) . Briefly, male and female hearts were perfused for 20 min in the dark and snap frozen in liquid nitrogen. All subsequent procedures were performed in the dark. Hearts were powdered on liquid nitrogen with a mortar and pestle and resuspended in 1.0 ml of homogenization buffer containing the following (in mmol/l): 300 sucrose, 250 HEPES-NaOH, pH 8.0, 1 EDTA, 0.1 neocuproine and 0.5% Triton-X 100. An EDTA-free protease inhibitor tablet (Roche, Indianapolis, IN) was added just before use. Samples were then homogenized using a Dounce glass homogenizer on ice and centrifuged at 14,000 g for 30 min to pellet debris. The supernatant was recovered as total crude homogenate. Protein concentration was determined using the Bradford protein assay. Total homogenates were then aliquoted and stored at Ϫ80°C.
SNO-RAC. SNO sites were identified using the SNO-RAC protocol, as previously described (22, 24) . Briefly, samples (whole heart homogenate; 1 mg) were diluted in HEN buffer containing the following (in mmol/l): 250 HEPES-NaOH, pH 8.0, 1 EDTA, and 0.1 neocuproine, with 2.5% SDS and an EDTA-free protease inhibitor tablet. All buffers were degassed before use to prevent oxidation of the resin; subsequent procedures were also performed in the dark. Homogenates were incubated with 50 mmol/l iodoacetamide for 20 min at 56°C to block unmodified thiol groups from modification; iodoacetamide was removed via acetone precipitation. Samples were then resuspended in HEN with 1% SDS (HENS). Thiopropyl sepharose resin (GE Healthcare, Piscataway, NJ) was rehydrated for 25 min in HPLC-grade water. Following rehydration, 25 l of the resin slurry were added to a Handee Mini Spin Column (Thermo Fisher, Waltham, MA) and washed with 5 ϫ 0.5 ml HPLC-grade water, followed by 10 ϫ 0.5 ml HEN buffer. Blocked samples were then added to the thiopropyl sepharose-containing spin column along with 20 mmol/l ascorbate and rotated for 4 h in the dark at room temperature. Resin-bound proteins were washed with 8 ϫ 0.5 ml HENS buffer, followed by 4 ϫ 0.5 ml HENS buffer diluted 1:10. Samples were then subjected to trypsin digestion (sequencing grade modified; Promega, Madison, WI) overnight at 37°C with rotation in 50 mmol/l NH 4HCO3. Resin-bound peptides were then washed with 5 ϫ 0.5 ml HENS buffer 1:10, 5 ϫ 0.5 ml 2 mol/l NaCl, 5ϫ 0.5 ml 80% acetonitrile, and 5 ϫ 0.5 ml HPLC-grade water. Resin-bound peptides were then eluted for 15 min at room temperature in elution buffer containing the following (in mmol/l): 20 dithiothreitol and 10 NH4CO3. The resin was then washed with an additional volume of elution buffer. All fractions were combined and concentrated by SpeedVac (Thermo Fisher) and resuspended in 50 mmol/l NH4HCO3, and all detergent was removed using HiPPR columns (Thermo Fisher) per the manufacturer's instruction. Samples were then resuspended in 0.1% formic acid and cleaned with C18 column ZipTips (EMD Millipore, Billerica, MA) before liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis.
LC-MS/MS analysis and database search. LC-MS/MS was performed using an Eksigent nanoLC-Ultra 1D plus system (Dublin, CA), coupled to an LTQ Orbitrap Elite mass spectrometer (Thermo Fisher) using collision-induced dissociation fragmentation. Peptides were first loaded onto a Zorbax 300SB-C18 trap column (Agilent, Santa Clara, CA) at a flow rate of 6 l/min for 6 min, and then separated on a reversed-phase PicoFrit analytic column (New Objective, Woburn, MA) using a 40-min linear gradient of 5-40% acetonitrile in 0.1% formic acid at a flow rate of 250 nl/min. LTQ Orbitrap Elite settings were as follows: spray voltage 1.5 kV, and full MS mass range: mass-to-charge ratio 230-2,000. The LTQ Orbitrap Elite was operated in a data-dependent mode [i.e., one MS1 high resolution (60,000) scan for precursor ions, followed by six data-dependent MS/MS scans for precursor ions above a threshold ion count of 2,000 with collision energy of 35%]. Raw files generated from the LTQ Orbitrap Elite were analyzed using Proteome Discoverer 1.4 (Thermo Fisher) with the MASCOT database search engine. The following search criteria were used: database, Swiss-Prot (Swiss Institute of Bioinformatics); taxonomy, Mus musculus (mouse); enzyme, trypsin; miscleavages, 3; variable modifications, oxidation (M), carbamidomethyl (C), deamidation (NQ); MS peptide tolerance, 25 ppm; MS/MS tolerance, 0.8 Da. Peptides were filtered at a false discovery rate of 1%.
Label-free peptide quantification. The label-free peptide quantification feature of Proteome Discoverer 1.4 was used to determine the ratio or relative abundance for a given SNO-modified residue. This label-free peptide quantification function uses a proprietary algorithm to calculate the area for each peptide based on the area-under-thecurve peak for a given peptide from each LC-MS/MS run. Quantitative ratios were then obtained by normalizing the peptide peak areas against a chosen reference (i.e., baseline male heart for common peptides). The resulting ratios reflect the relative quantity of a peptide (and hence the corresponding SNO level) in different samples.
Western blot. Samples were separated on a 4 -12% Bis-Tris SDS-PAGE gel and transferred onto a nitrocellulose membrane (Life Technologies). Membranes were blocked with 5% (wt/vol) nonfat dried milk or 5% (wt/vol) bovine serum albumin (for phospho-eNOS) in Tris-buffered saline with 0.1% Tween 20 for 1 h, and subsequently incubated with primary antibodies against eNOS (1:250; Santa Cruz Biotechnology, Dallas, TX), phospho-eNOS Ser1177 (1:1,000; Cell Signaling), nNOS (1:250; Santa Cruz Biotechnology), inducible NOS (iNOS) (1:250; Santa Cruz Biotechnology), GSNO-R (1:1,000; Origene, TA3211174), sarcoplasmic/endoplasmic reticulum Ca 2ϩ -ATPase 2a (SERCA2a) (1:1,000; Santa Cruz Biotechnology), aconitase (1:1,000; Cell Signaling, 6922), or GAPDH (1:1,000; Santa Cruz Biotechnology). Membranes were then probed with the corresponding secondary antibodies for 1 h and visualized by electrogenerated chemiluminescence (Life Technologies). Densitometry was assessed using ImageJ software (National Institutes of Health, Bethesda, MD).
Measurement of NO x production. NOx production, including nitrite and nitrate, was measured using an ultrasensitive colorimetric kit (Oxford Biomedical Research, Oxford, MI), per the manufacturer's instruction with minor modifications. All subsequent procedures were performed in the dark. Briefly, male and female hearts were cleared of blood with KHB and homogenized using a Polytron (Kinematica, Bohemia, NY) in 500 l of NO x assay buffer as follows (in mmol/l): 10 HEPES, 10 EDTA, 10 EGTA, and 250 Tris·HCl, pH 7.4. Homogenates (500 g) were then diluted in NOx assay buffer in the presence of the following NOS cofactors: L-arginine, NADPϩ, glucose 6-phosphate, and glucose 6-phosphate dehydrogenase (collectively herewithin, NADPH). Selective and nonselective NOS inhibitors were also utilized as indicated; SMLT (5 nmol/l) was used as a selective nNOS inhibitor, whereas L-NIO (10 mol/l) was used as a nonselective NOS inhibitor. Samples were then incubated for 3 h at 37°C, followed by the addition of nitrate reductase to convert all nitrate to nitrite. Griess reagent was then added to quantify NO x production.
GSNO-R activity assay. GSNO-R activity was assessed in whole heart homogenates, as previously described (18, 32) . Briefly, male and female hearts were rinsed in KHB and snap frozen in liquid nitrogen. Hearts were then homogenized in cell lysis buffer (Cell Signaling, Danvers, MA) with protease/inhibitor cocktail (Cell Signaling) using a Polytron (Kinematica). Homogenates (100 g) were then diluted in assay buffer as follows (in mmol/l): 20 Tris·HCl, pH 8.0, 0.5 EDTA, 0.5 neocuproine, with 0.1% NP-40 and protease/phosphatase inhibitor cocktail (Cell Signaling). NADH (200 mol/l) and GSNO (400 mol/l) were then added to initiate the reaction, and NADH consumption was monitored via absorbance at 340 nm over 30 min at 25°C. GSNO-R activity was then calculated as the rate of NADH consumption in samples containing GSNO, after subtracting the background rate of NADH consumption in samples that did not contain GSNO. Whole lung and kidney homogenates were prepared and assayed using the same method, with the exception that 800 g of total lung homogenate were used for the assay.
Statistics. Results are expressed as means Ϯ SE. Statistical significance (P Ͻ 0.05) was determined between groups using a Student's t-test for two groups or a two-way ANOVA with Tukey's multiple comparison correction for multiple groups.
RESULTS
Model of sex-dependent cardioprotection.
To confirm our model of sex-dependent cardioprotection, we subjected Langendorff-perfused male and female hearts to I/R injury ( n ϭ 4 Hearts/group. False discovery rate (FDR): 1%. These S-nitrosothiol (SNO) protein identifications were not observed in female samples. Italicized SNO proteins were identified in only a single male sample (i.e., one-hit peptides), whereas all other SNO proteins were identified in more than one sample. "SNO cysteine" represents the modified residue. RAC, resin-assisted capture; LC-MS/MS, liquid chromatography-tandem mass spectrometry.
These results confirm that female hearts show protection against I/R injury.
Sex differences in myocardial protein SNO. To identify a potential role for protein SNO in sex-dependent cardioprotection, we utilized SNO-RAC in tandem with LC-MS/MS as a high-throughput approach to identify specific SNO sites in male and female hearts. In total, we identified 185 different SNO proteins in male and female hearts at baseline (Supplemental Tables S1 and S2 ; Supplemental Material for this article is available online at the Journal website), and, consistent with previous reports, we found that female hearts exhibited nearly 65% more unique SNO protein identifications compared with male hearts (Fig. 2A) . Interestingly, a number of these femalespecific SNO proteins have not been previously reported. Of the proteins identified, 76 were unique to female hearts (i.e., proteins only detected in female samples, but not detected in male samples), and 8 were unique to male hearts (i.e., proteins only detected in male samples, but not detected in female samples) (Fig. 2B) . Unique SNO proteins in male hearts included pyruvate dehydrogenase kinase 1, ␤-taxilin, and hemopexin (Table 1) , while unique SNO proteins in female hearts included cyclophilin D, heat shock protein 60, and glutathione S-transferase-( Table 2, Supplemental Table S3 ). Interestingly, many of the unique identifications in female hearts overlap with those observed in other forms of cardioprotection, including protein DJ-1 and the F 1 F O -ATPase (24, 47, 49) . Furthermore, Ingenuity Pathway Analysis revealed a high prevalence of SNO proteins in the mitochondrial compartment of female hearts, with targets involved in oxidative phosphorylation and the citric acid cycle ( Table 3 ). The results suggest that, in general, female hearts maintain a higher level of protein SNO protein at baseline compared with males. Please note that the male and female proteomic datasets described above include all SNO protein identifications, including SNO proteins that were only detected in one sample per group (i.e., observed in 1 of 8 samples). However, 71% of the SNO proteins in male hearts and 78% of the SNO proteins in female hearts were identified in at least two or more samples.
We also utilized label-free peptide analysis to quantify levels of the 101 common identifications (i.e., proteins detected in both male and female samples) between male and female hearts (Supplemental Table S4 ). In an effort to increase confidence, we focused specifically on peptides that were detected in all samples for a given group (i.e., in eight of eight samples). Although the majority of common SNO proteins exhibited similar SNO levels in male and female hearts (Table 4) , including glyceraldehyde-3-phosphate dehydrogenase, ␤-enolase, and triosphosphate isomerase, we noted that SNO of the SERCA2a at Cys344 was nearly 70% lower in male hearts compared with female (Fig. 3A) , independent of protein expression (Fig. 3B) . Conversely, SNO of aconitase at Cys385 was 67% higher in male hearts (Fig. 3C) , and this was also independent of protein expression (Fig. 3D) . Since SERCA2a and aconitase are localized to different compartments in the cardiomyocyte (SERCA2a to the sarcoplasmic reticulum and aconitase to the mitochondria), these results support a potential role for differential regulation and/or localization of protein SNO in male and female hearts.
SNO-RAC reproducibility. The reproducibility of our SNO-RAC approach is detailed in our laboratory's prior publications (22, 24) . In the present study, we utilized biological replicates (n ϭ 4 -8 hearts/group) and maintained a similar level of reproducibility, as demonstrated in Fig. 4 , which depicts high overlap between two representative biological replicates for both male and female hearts. In addition, Ͼ50% of our reported SNO peptide identifications were observed in at least one-half of the total samples comprising each group (i.e., observed in at least 4 of 8 samples).
NO/SNO regulation in male and female hearts. To identify potential sources for increased protein SNO in the female heart, we next examined each of the NOS isoforms for potential protein expression differences. We found that eNOS levels were significantly higher in female mouse hearts compared with males (Fig. 5A ), as were eNOS phosphorylation levels at Ser1177 (Fig. 5B ). nNOS expression was not different in male and female mouse hearts (Fig. 5C) , and iNOS expression was not detected (Fig. 5D) . We also quantified NO x production in whole heart homogenates. Consistent with our observed increase in eNOS expression and phosphorylation, we detected significantly higher NO x production in female myocardium compared with male (Fig. 6) . Selective inhibition of nNOS with SMLT had no effect on NO x production in male or female myocardium, while nonselective inhibition of NOS activity n ϭ 8 Hearts/group. FDR: 1%. These SNO protein identifications were not observed in male samples. Italicized SNO proteins were identified in only a single female sample (i.e., one-hit peptides), whereas all other SNO proteins were identified in more than one sample. "SNO cysteine" represents the modified residue. with L-NIO significantly decreased NO x production. Taken together, these results suggest that eNOS may be responsible, in part, for increased NO x production and SNO protein levels in the female heart. Although increased eNOS likely contributes to the enhancement of SNO levels in female hearts, GSNO-R may also play an important role in regulating protein SNO levels by mediating catabolism. Therefore, we also examined GSNO-R expression and activity in male and female mouse hearts. We found no difference in GSNO-R expression (Fig. 7A ), but activity was significantly higher in whole heart homogenates from females compared with males (Fig. 7B) . As a positive control for the assay, we also examined GSNO-R activity in the lung and kidney and found that activity was nearly twofold higher in the female lung compared with males (male: 10. , P ϭ 0.56; n ϭ 6 kidneys/group). These results are consistent with previously published results (7). Thus GSNO-R does not appear to contribute to the enhancement of SNO levels that we observed in female hearts.
DISCUSSION
In the present study, we report for the first time a comprehensive characterization of the sex-dependent myocardial SNO proteome. We first confirmed our model of sex-dependent cardioprotection by demonstrating that female hearts exhibit greater functional recovery following I/R injury compared with male hearts using a Langendorff-perfused heart model ( Fig. 1) . These results are consistent with previous studies (3, 20, 44, 51) . We next utilized SNO-RAC in tandem with mass spectrometry to identify SNO proteins and modification sites in male and female hearts and noted that SNO protein identifications were nearly 65% greater in female hearts compared with male hearts (Fig. 2) . These results are consistent with our laboratory's previous study demonstrating enhanced SNO levels in membrane fractions from female hearts compared with males, but specific SNO sites were not identified (48) . Herein, we identified a number of unique SNO proteins and modification sites in both male (Table 1, Supplemental Table S1) and  female (Table 2, Supplemental Tables S2 and S3 ) hearts, as well as many overlapping SNO protein identifications (Table 4,  Supplemental Table S4 ). For common SNO protein identifications, we used label-free peptide quantification to assess SNO levels at specific modification sites and determined that SNO of n ϭ 4 -8 Hearts/group. FDR: 1%. Proteins were identified in all samples for a given group (i.e., eight out of eight). "SNO cysteine" represents the modified residue. Label-free peptide quantification was used to determine the ratio or relative abundance for a given SNO cysteine residue (i.e., SNO level). SERCA2a at Cys344 was more than threefold greater in female hearts, while SNO of aconitase at Cys385 was 67% higher in male hearts (Fig. 3) . Since SERCA2a is localized to the sarcoplasmic reticulum and aconitase to the mitochondria, these results support the potential for differential SNO signaling and compartmentalization in male and female hearts. Assay reproducibility was also comparable to that observed in previous studies (22, 24) , as seen in Fig. 4 . To determine a mechanistic source for enhanced SNO levels in female hearts, we examined the expression of each of the NOS isoforms and noted that eNOS expression was significantly higher in female hearts compared with males, as was phosphorylation of eNOS at Ser1177 (Fig. 5) , a known activation site (34). nNOS expression was not different between male and female hearts, and iNOS was not detected. Consistent with our laboratory's prior study (10) and the increase in eNOS expression and phosphorylation, we also observed higher NO x production in female hearts compared with males (Fig. 6 ). In addition, we found that nNOS inhibition was without effect on NO x production in female hearts, while nonselective NOS inhibition significantly attenuated the difference in NO x production. Thus nNOS and iNOS are unlikely to contribute to the difference in SNO protein levels. We finally examined the expression and activity of GSNO-R, which is a major enzyme involved in SNO protein catabolism, but there was no expression difference in male and female hearts (Fig. 7) . However, we detected a significant increase in GSNO-R activity in female hearts compared with males, which suggests that GSNO-R is unlikely to be responsible for the observed difference in SNO levels and may actually be functionally elevated in response to increased SNO in female hearts, thereby minimizing the sex-dependent difference in protein SNO. Taken together, these results support a potential mechanism whereby increased eNOS expression and phosphorylation leads to the enhancement of protein SNO in the female heart compared with males (Fig. 8) . SNO and sex-dependent cardioprotection. Sex-dependent cardioprotection is thought to primarily occur through the beneficial effects of estrogen, which can signal via changes in gene expression and/or the activation of acute signaling pathways (36) . A number of studies have demonstrated cardioprotective effects with estrogen administration in animal models utilizing both male and female hearts (5, 6, 12, 28, 46) . Conversely, ovariectomy blocks sex-dependent protection, while estrogen restoration via minipump administration of 17␤-estradiol or 2,2-bis(4-hydroxyphenyl)-proprionitrile not only restores cardioprotection in overectomized female mice, but also increases protein SNO levels in the heart (31) . A number of these SNO protein targets observed with 17␤-estradiol or 2,2-bis(4-hydroxyphenyl)-proprionitrile treatment overlap with those identified in the present study with intact female hearts (Table 5 ). Protein SNO levels are also increased in many different models of cardioprotection, as we have demonstrated with ischemic preconditioning and postconditioning, as well as pharmacological agents (24, 47, 49) . Sexdependent cardioprotection may work through a similar mechanism (Fig. 2) , as considerable overlap is observed between these various cardioprotective interventions. Table 5 is a comprehensive comparison of common SNO proteins and modification sites resulting from different cardioprotective interventions, some of which may serve as important nodes for cardioprotective signaling. Please note that the varying degrees in overlap between the different interventions may result, in part, from differences in methodology (17) . For example, gel-based approaches are not effective for examining high-molecular weight and/or membrane proteins, whereas LC-MS/MS-based approaches are limited to peptides that can ionize properly during mass spectrometry analysis.
Protein SNO is thought to provide cardioprotection, in part, by modulating the activity of target proteins. Our laboratory previously demonstrated that SNO of the L-type Ca 2ϩ channel was enhanced in female mouse hearts, and this correlated with reduced channel activity and decreased Ca 2ϩ overload following I/R injury (48) . Increased SNO of SERCA2a at Cys344 may play a similar role in female hearts by regulating Ca 2ϩ levels in the cardiomyocyte (Fig. 3) . A number of studies have noted slowed relaxation kinetics in cardiomyocytes isolated from female hearts compared with male, suggestive of decreased SERCA2a activity in female cardiomyocytes (11, 27, 52) . In contrast, our laboratory previously demonstrated a dose-dependent increase in SERCA2a activity with the Snitrosylating agent GSNO (47) . However, neither study identified specific SNO sites for SERCA2a. Our laboratory previously identified SNO of SERCA2a at Cys344 with myocardial postconditioning (49), but SERCA2a activity was not measured in this study. Interestingly, S-glutathionylation of SERCA2a at Cys674 has been shown to increase activity (1), demonstrating that cysteine modifications can potentially regulate the activity of SERCA2a. Regarding the physiological ramifications of increased SNO-aconitase in male hearts (Fig.  3) , NO can inhibit aconitase activity (50) . Aconitase activity has also been shown to be decreased in male brain mitochondria compared with females (43) , although the authors conclude that this decrease results from increased reactive oxygen species production in male brain mitochondria. Nonetheless, it is interesting to speculate that perhaps SNO may also be involved in the regulation of aconitase activity, possibly as a Fig. 6 . Baseline total nitric oxide (NOx) production in male and female hearts. NOx production was assessed in male and female hearts using a colormetric assay (male: solid bars, female: shaded bars; n ϭ 4 hearts/group). SMLT,
Values are means Ϯ SE. #P ϭ 0.075 vs. male ϩ NAPDH, ϪSMLT, ϪL-NIO. *P Ͻ 0.05 vs. male ϩNAPDH, ϪSMLT, ϪL-NIO. **P Ͻ 0.05 vs. female ϩNAPDH ϪSMLT ϪL-NIO. SMLT (5 nmol/l) was used as a selective inhibitor of nNOS, and L-NIO (10 mol/l) was used as a nonselective NOS inhibitor. Fig. 7 . S-nitrosoglutathione reductase (GSNO-R) expression and activity in male and female hearts. A: GSNO-R expression was assessed in male and female hearts via Western blot (n ϭ 4 hearts/group; primary antibody: Origene, TA3211174, 1:1,000 dilution). B: GSNO-R activity was examined in male and female hearts (n ϭ 11 hearts/group). Values are means Ϯ SE. Male: solid bars; female: shaded bars. *P Ͻ 0.05.
way to modulate the activity of the citric acid cycle. However, it is important to note that enhanced SNO-aconitase levels in male heart mitochondria appear to be the exception, as mitochondrial SNO is generally higher in female hearts compared with male.
Protein SNO also provides protective effects by blocking the irreversible oxidation of critical cysteine residues that may occur with conditions such as I/R injury or oxidative stress, as our laboratory and others have shown (8, 23, 24) . Consistent with this protective effect, we identified a high number of SNO proteins in the mitochondrial compartment of female hearts, and, since mitochondria are a major source of reactive oxygen species during I/R injury (53), modification of these proteins via SNO may serve as a crucial barrier to protect critical cysteine residues against irreversible oxidative damage. In addition, our laboratory previously reported a decrease in reactive oxygen species production in isolated female heart mitochondria compared with males following anoxia and reoxygenation (26), which was attributed, in part, to differences in the phosphorylation of various mitochondrial enzymes in the female heart. SNO may also play a similar role, thereby decreasing reactive oxygen species production and the potential for irreversible cysteine oxidation.
Regulation of myocardial protein SNO levels. Activation of NOS and the production of NO are known to be cardioprotective. eNOS and nNOS are the primary source of NO in cardiomyocytes (15) , and NOS expression is increased in female hearts compared with male (48) . Estrogen is also associated with the upregulation of eNOS expression (33, 41) . Consistent with these reports, we noted increased eNOS expression in female mouse hearts compared with male (Fig. 5) , with no difference in nNOS expression (Fig. 6) . We also detected higher eNOS phosphorylation at Ser1177, a known activation site (34), in female mouse hearts compared with male (Fig. 5) . Since we examined eNOS expression and phosphorylation in whole heart homogenates, we cannot rule out the contribution of endothelial cell-derived eNOS. However, NO is membrane diffusible, and eNOS mRNA levels have been shown to be increased in isolated female cardiomyocytes compared with male (14) . Interestingly, our laboratory's previous study demonstrated that inhibition or genetic deletion of eNOS or nNOS abrogated cardioprotection in female hearts in a hypercontractile model of I/R injury (48) , which suggests that eNOS and nNOS are both essential for sex-dependent cardioprotection. However, at baseline, the loss of nNOS had a marginal effect on SNO levels in membrane fractions in male and female hearts, while the loss of eNOS decreased SNO levels below the limit of detection. Since our model of I/R injury did not incorporate a hypercontractile component, the relative contributions of eNOS and nNOS may be different from that observed in our previous study. In addition, the potential exists for differences in enzyme activity and/or NO x production between the sexes. Indeed, we detected a significant, eNOS-dependent increase in NO x production in female hearts compared with males (Fig. 6 ). This is consistent with our laboratory's previous study in which we observed a trend toward increased NO x levels at baseline in hearts from 129J female mice compared with males (10) . In addition, Ruiz-Holst et al. (45) utilized immunohistochemical staining to demonstrate that eNOS phosphorylation was increased at Ser1177 in female cardiomyocytes, along with the cytosolic translocation of eNOS, suggesting that eNOS activity may be higher in female hearts compared with male, but eNOS activity was not directly measured. Our laboratory's previous studies also show that ischemia induces a greater male-female difference in NO x production and SNO levels in membrane fractions (10, 48) , suggesting that the stress response to ischemia is greater in female hearts.
The difference in eNOS expression, phosphorylation, and NO x production between male and female hearts may partly explain the enhanced SNO levels, but GSNO-R also plays a role in regulating SNO levels by mediating catabolism. Genetic deletion of GSNO-R has been shown to be protective in male hearts (30) , likely due in part to enhanced protein SNO levels, but sex differences were not examined. We observed no difference in GSNO-R expression between male and female hearts (Fig. 7) . However, GSNO-R activity was significantly higher in female hearts compared with males; thus GSNO-R is unlikely to contribute to the increase in SNO levels observed in female hearts. This result is consistent with the results of Brown-Steinke et al. (7), who showed that GSNO-R expression is similar in the male and female lung, while GSNO-R activity is increased in the female lung due to enhanced SNO of the enzyme. However, in the present study, we did not examine the SNO status of GSNO-R, leaving open the possibility that SNO is responsible for the increase in GSNO-R activity found in female hearts. Nonetheless, our observed increase in GSNO-R activity may play an important role in the female heart by serving as a brake to prevent SNO from reaching pathological levels and triggering nitrosative stress. As a result, the balance between increased NO x production and increased SNO catabolism in the female heart allows for the maintenance of enhanced protein SNO levels, which are protective against myocardial I/R injury (Fig. 8) .
Role of posttranslational modifications in cardioprotection. In the present study, we focused on a single posttranslational Fig. 8 . Model of sex-dependent cardioprotection. Female hearts exhibit higher myocardial eNOS expression, phosphorylation (P), and NOx production, which facilitates enhanced SNO protein levels to induce a cardioprotective phenotype; enhanced GSNO-R activity in the female heart may also play a role in this pathway by preventing protein SNO from accumulating to levels that are sufficient to trigger nitrosative stress. Conversely, male hearts exhibit reduced myocardial eNOS expression, phosphorylation, and NOx production, thus leading to a level of protein SNO that falls below a critical threshold for cardioprotection; SNO protein levels can be increased in male hearts to facilitate cardioprotection with interventions, including ischemic preconditioning (IPC) (24, 47 Table 5 . Regardless of the model of cardioprotection, there appears to be a number of proteins that are consistently modified via SNO, some at the same cysteine residue. These proteins include aconitase, ␤-enolase, electron transfer flavoprotein-␣, fructose-bisphosphate aldolase A, SNO proteins were identified using different cardioprotective strategies in multiple species with various methodologies, as noted at the top of the table. "SNO cysteine" represents the modified residue (if available); "⌬ from control male" represents the ratio or relative abundance for a given SNO protein or cysteine residue (i.e., SNO level) compared with control male heart, as noted in the study indicated, and can be found in parentheses next to the SNO modification site (if available); ND indicates that the ⌬ from control male was not determined. DIGE, difference gel electrophoresis; HPAEC, human pulmonary artery endothelial cells.
glyceraldehyde-3-phosphate dehydrogenase, and the voltagedependent anion-selective channel protein (VDAC) ( Table 5) . Although our laboratory and others have demonstrated that SNO plays an important role in cardioprotection, additional posttranslational modifications are also likely to play critical roles as well, and these include phosphorylation, O-GlcNAcylation, and acetylation. For example, the ␤-subunit of the F 1 F O -ATPase has been shown to be more highly phosphorylated with pharmacological preconditioning (2), but effects on function were not explored. In our cardioprotection studies, we have detected SNO on additional subunits of the F 1 F O -ATPase (31, 47, 49) . In addition, VDAC is a common target of SNO in various forms of cardioprotection, but the phosphorylation status of VDAC also appears to play a role in cardioprotection (13) . VDAC is also a target of O-GlyNAcylation during ischemic preconditioning (21) , and this VDAC modification appears to be important in the regulation of the mitochondrial permeability transition pore (39) . A number of additional targets were also identified to be O-GlcNAcylated, and these include heat shock protein 60, glyceraldehyde-3-phosphate dehydrogenase, and the cytoplasmic and mitochondrial isoforms of malate dehydrogenase (21) , all of which were identified as SNO-modified proteins in the present study. There is also a degree of overlap among proteins modified via SNO in cardioprotection and those that are modified through protein acetylation. These proteins targets include VDAC, SERCA2a, and the ␣-and ␤-subunits of the mitochondrial electron transfer flavoprotein complex (16) . Although a number of proteins have been identified as specific targets of various posttranslational modifications in cardioprotection, the specific role(s) of individual and tandem modifications remains to be fully elucidated. The interactions and interplay between these posttranslational protein modifications also remains poorly defined, but a barcode for phosphorylation has been described in the regulation of the ␤ 2 -adrenergic receptor and ␤-arrestin (40) , and this barcode of posttranslational modifications could well apply to additional protein modifications.
Potential limitations. There are a number of potential limitations that require acknowledgement. The method utilized in the present study favors high-abundance peptide identifications. Consequently, peptides of low abundance and/or low SNO levels may not be detected in a given sample/group, despite the presence of these peptides. Detection of a given peptide or lack thereof for a given sex does, however, potentially represent a protein target with a substantial difference in the level of SNO between the sexes and may contribute to male-female differences in response to I/R injury. The present study also utilized whole heart homogenates rather than specific subcellular fractions (i.e., mitochondria, etc.), and this has the potential to compromise the depth of proteome coverage for the same reasons of protein abundance described previously. Therefore, the absolute number of SNO proteins observed in male and female hearts is likely to exceed that reported in the present study.
Conclusions. In summary, we demonstrated that female hearts exhibit greater functional recovery following I/R injury. We also found that female hearts maintain a higher level of protein SNO compared with males, and this increase in protein SNO may contribute, in part, to the female-specific cardioprotection observed in response to I/R injury. We also identified the potential for compartmentalized regulation of SNO with regard to specific protein targets and further determined that eNOS expression, phosphorylation, and NO x production were higher in female hearts compared with males, likely contributing to the enhancement of protein SNO in female hearts. This study has characterized the sex-dependent myocardial SNO proteome and provided mechanistic insight into the regulation of SNO protein levels in the male and female heart and also identified a number of novel SNO proteins in female hearts that may contribute to sex-dependent cardioprotection.
